This site is intended for US healthcare professionals only.

For the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF)PERTZYE® (pancrelipase)
mechanism of action

Discover how PERTZYE works within the digestive system1-4

Tap numbers below to reveal more information.

The pancreas releases pancreatic enzymes and bicarbonate into the duodenum. The duodenum is the first portion of the small intestine.
CF causes the mucus that coats and protects the digestive system to become abnormally thick and sticky.
See what happens when PERTZYE capsules enter the stomach.
Healthy digestive systemThe role of the exocrine
pancreas in healthy
CF patients with EPIPancreatic function in patients with EPI
How PERTZYE worksThe PERTZYE difference
Watch the PERTZYE MOA video

Watch the video to see how PERTZYE works within the digestive system.

Lipase requires an alkaline pH for optimal activity5

  • Lipase is one of the key ingredients of PERTs5
  • Lipase is most active at pH 8–95
  • Lipase activity decreases as pH decreases, and becomes irreversibly inactive at pH <46
pH scale
Proton pump inhibitors (PPIs) may not be the right fit for all CF patients

PPIs are sometimes used in conjunction with PERTs to reduce gastric acidity and indirectly affect duodenal pH.7-9

PPIs lack sufficient evidence showing they affect the efficacy of PERTs

An analysis of clinical trial data suggests that concomitant use of PPIs with PERTs does not improve efficacy, as determined by fat absorption values at the end of treatment.10

PPIs are associated with increased risk of adverse consequences

The adjunctive use of PPIs and H2 antagonists may be associated with:

  • Increased risk of community- and hospital-acquired pneumonia11
  • Increased risk of Clostridium difficile–associated diarrhea12
  • Osteoporosis-related bone fractures13
  • Risk of dementia14
  • Chronic kidney disease15

Adding a PPI increases pill burden and may affect patient compliance16